INSM

Insmed Incorporated

A maker of inhaled medicines for rare lung diseases, Insmed sells ARIKAYCE for a stubborn bacterial lung infection and BRINSUPRI for bronchiectasis, with gene therapies for muscular dystrophy and ALS in the works. Founded in 1988 in Richmond, Virginia, it began by developing insulin-like growth factor proteins before turning to respiratory care. Its ARIKAYCE was the first drug approved under the FDA's Limited Population Pathway, designed for serious infections in small patient groups.